A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Eric Christenson, Daruka Mahadevan, Syed Mohammad Ali Kazmi, Sudhir Manda, Davendra Sohal, Thomas E. Hutson, Siqing Fu, Ashley Martz, Stephanie Kordahi, Emilia Alina Barbu, Dallas Flies, Solomon Langermann, Michael Jon Chisamore, Martin Gutierrez, Marc Ryan Matrana, Alex Spira, Raymond Couric Wadlow, Udayan Guha, Han Myint, Dung T. Le
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The University of Texas at San Antonio Health Science Center, The University of Texas Southwestern Medical Center, Arizona Oncology, University of Cincinnati, University of Cincinnati Medical Center, Texas Oncology, The University of Texas MD Anderson Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Hackensack University Medical Center, Ochsner Health System, Ochsner Medical Center, Inova Fairfax Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399599995